BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 33131194)

  • 1. C1q-binding DSA and allograft outcomes in pediatric kidney transplant recipients.
    Hayde N; Solomon S; Caglar E; Ge J; Qama E; Colovai A
    Pediatr Transplant; 2021 Mar; 25(2):e13885. PubMed ID: 33131194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
    Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
    Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of complement-fixing donor-specific antibodies identified by a C1q assay after heart transplantation.
    Farrero Torres M; Pando MJ; Luo C; Luikart H; Valantine H; Khush K
    Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28940521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Int; 2017 Apr; 30(4):347-359. PubMed ID: 27717025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence and clinical significance of C1q-binding donor-specific anti-HLA antibodies early and late after kidney transplantation.
    Calp-Inal S; Ajaimy M; Melamed ML; Savchik C; Masiakos P; Colovai A; Akalin E
    Kidney Int; 2016 Jan; 89(1):209-16. PubMed ID: 26535999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation.
    Wozniak LJ; Hickey MJ; Venick RS; Vargas JH; Farmer DG; Busuttil RW; McDiarmid SV; Reed EF
    Transplantation; 2015 Jul; 99(7):1416-22. PubMed ID: 26038872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transplant development of C1q-positive HLA antibodies and kidney graft survival.
    Piazza A; Poggi E; Ozzella G; Adorno D
    Clin Transpl; 2013; ():367-75. PubMed ID: 25095531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of C1q Binding Status With De Novo HLA Antibody Clinical Features and Allograft Function in Kidney Transplantation Patients During Eight Years of Dynamic Follow-up.
    Wei X; Yuan X; Sun M; Pan Z; Hu L; Wang L; He J; Hou J
    Transplant Proc; 2016; 48(6):1944-54. PubMed ID: 27569927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preformed C1q-binding Donor-specific Anti-HLA Antibodies and Graft Function After Kidney Transplantation.
    Okabe Y; Noguchi H; Miyamoto K; Kaku K; Tsuchimoto A; Masutani K; Nakamura M
    Transplant Proc; 2018 Dec; 50(10):3460-3466. PubMed ID: 30577221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Pretransplant Complement-fixing Donor-specific Antibodies Identified by C1q Assay in Kidney Transplantation.
    Thammanichanond D; Wiwattanathum P; Mongkolsuk T; Kantachuvesiri S; Worawichawong S; Vallipakorn SA; Kitpoka P
    Transplant Proc; 2016 Apr; 48(3):756-60. PubMed ID: 27234729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement-fixing donor-specific anti-HLA antibodies and kidney allograft failure.
    Cazarote HB; Shimakura S; Valdameri JS; Contieri FLC; von Glehn CQC; Aita CM; Susin MF; Sotomaior VS; Glehn-Ponsirenas R
    Transpl Immunol; 2018 Aug; 49():33-38. PubMed ID: 29596992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.
    Freitas MC; Rebellato LM; Ozawa M; Nguyen A; Sasaki N; Everly M; Briley KP; Haisch CE; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
    Transplantation; 2013 May; 95(9):1113-9. PubMed ID: 23514959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
    Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
    PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does a Useful Test Exist to Properly Evaluate the Pathogenicity of Donor-specific Antibodies? Lessons From a Comprehensive Analysis in a Well-studied Single-center Kidney Transplant Cohort.
    Gautier Vargas G; Olagne J; Parissiadis A; Joly M; Cognard N; Perrin P; Froelich N; Guntz P; Gachet C; Moulin B; Caillard S
    Transplantation; 2020 Oct; 104(10):2148-2157. PubMed ID: 31895344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The disappointing contribution of anti-human leukocyte antigen donor-specific antibodies characteristics for predicting allograft loss.
    Courant M; Visentin J; Linares G; Dubois V; Lepreux S; Guidicelli G; Thaunat O; Merville P; Couzi L; Taupin JL
    Nephrol Dial Transplant; 2018 Oct; 33(10):1853-1863. PubMed ID: 29672702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcome of Patients With De Novo C1q-Binding Donor-Specific HLA Antibodies After Renal Transplantation.
    Bamoulid J; Roodenburg A; Staeck O; Wu K; Rudolph B; Brakemeier S; Halleck F; Lehner L; Schönemann C; Lachmann N; Budde K
    Transplantation; 2017 Sep; 101(9):2165-2174. PubMed ID: 27653301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of complement binding assays to assess the efficacy of antibody mediated rejection therapy and prediction of graft survival in kidney transplantation.
    Ramon DS; Huang Y; Zhao L; Rendulic T; Park JM; Sung RS; Samaniego M
    Hum Immunol; 2017 Feb; 78(2):57-63. PubMed ID: 27894836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients.
    Zeevi A; Lunz J; Feingold B; Shullo M; Bermudez C; Teuteberg J; Webber S
    J Heart Lung Transplant; 2013 Jan; 32(1):98-105. PubMed ID: 23142561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation.
    Bailly E; Anglicheau D; Blancho G; Gatault P; Vuiblet V; Chatelet V; Morelon E; Malvezzi P; Parissiadis A; Tourret J; Guidicelli G; Sayegh J; Mousson C; Grimbert P; Top I; Le Quintrec M; Purgus R; Westeel PF; Proust B; Chabot V; Lebranchu Y; Dehaut F; Büchler M
    Transplantation; 2018 Apr; 102(4):688-698. PubMed ID: 29135832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.